Compare BioNano Genomics Inc (BNGO) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Palantir Technologies Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.77M), while Palantir Technologies Inc trades at $171.2 (market cap $411.02B). The key difference: Palantir Technologies Inc is far larger — about 29848.9× BioNano Genomics Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PLTR | |
|---|---|---|
Market Cap | $13.77M | $411.02B |
Sector | Health | Technology |
52-Week High | $4.92 | $207.18 |
52-Week Low | $1.06 | $107.27 |
Enterprise Value | $16.38M | $401.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
PLTR trades at $171.42, down 2.16% on the day, with a bullish technical trend supported by moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.41 actual versus $0.3446 expected, and revenue growth accelerated to $4.48 billion in 2025. Analyst consensus is bullish with a $213.44 price target, though high valuation ratios like a P/E of 149.52 pose concerns.
Outlook remains positive due to robust earnings growth and AI-driven demand, but risks include elevated valuations, insider selling, and bearish sentiment from notable investors like Michael Burry. The stock offers upside to consensus targets but requires monitoring for sustainability of profit margins and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
